First patient enrolled in Phase 3 trial of PAH treatment IKT-001
WHY IT MATTERS
If you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation of imatinib, in people with pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH trial (NCT07365332) is expected to enroll nearly 500 adults with various forms of PAH, ages 18 to 75, who are on stable treatment with […] The post First patient enrolled in Phase 3 trial of PAH treatment IKT-001 appeared first on Pulmonary Hypertension News
YOU CAN ACT ON THIS
Check if you meet the eligibility criteria (age 18-75, diagnosed PAH, on stable treatment) and ask your pulmonary hypertension specialist if you should consider enrolling in the IMPROVE-PAH trial (NCT07365332).